Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials

Background: We review factors impacting ipilimumab-associated adverse events through the experience from National Cancer Institute (NCI)-sponsored phase I immunotherapy clinical trials. Materials and Methods: Attributable ipilimumab-related adverse events from NCI-sponsored phase I immunotherapy cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Aman, Kabir, Tanvir, Wu, Jianrong, Wei, Jing, Cook, Mary, Kunos, Charles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185063/
https://www.ncbi.nlm.nih.gov/pubmed/32363000
http://dx.doi.org/10.18632/oncotarget.27537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185063/
https://www.ncbi.nlm.nih.gov/pubmed/32363000
http://dx.doi.org/10.18632/oncotarget.27537

Ejemplares similares